Novanta Inc. (NOVT) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call and Q&A reveal a positive outlook for Novanta. Despite a slight decline in gross margin, strong growth is evident in multiple segments, such as Medical Solutions and Automation Enabling Technologies. The company's strategic initiatives, including regionalization and new product launches, are expected to drive future growth. The NVIDIA AI lab certification and strong bookings further bolster confidence. Although some uncertainties remain, particularly in cost management, the overall sentiment is optimistic, suggesting a likely stock price increase of 2% to 8% over the next two weeks.
Key Financial Performance
Revenue Growth 10% reported growth and 3% organic growth year-over-year. Reasons for change include new product momentum and strong commercial execution.
Bookings 37% year-over-year growth with a book-to-bill ratio of 1.10. Reasons for change include continued new product momentum and strong commercial execution.
Adjusted EBITDA 14% year-over-year growth with a 70 basis points margin expansion. Reasons for change include strong profit performance and operational efficiency.
Adjusted Diluted EPS 9% year-over-year growth. Reasons for change include strong profitability and operational execution.
Operating Cash Flow 63% year-over-year growth. Reasons for change include strong profitability, sales linearity, and strong customer collections.
Medical Consumables Revenue 15% of total company revenue with double-digit growth trajectory. Reasons for change include strong demand and scaling of medical consumables business.
Robotics & Automation Revenue High single-digit revenue growth in the first quarter. Reasons for change include GenAI-driven tailwinds, new product advancements, and recovering semiconductor markets.
Precision Manufacturing Revenue Mid-single-digit growth in the first quarter. Reasons for change include rising automation and digitization of manufacturing lines.
Precision Medicine Revenue Double-digit revenue growth in the first quarter. Reasons for change include the Keonn acquisition and modest growth in the core business.
New Product Revenue 50% year-over-year growth. Reasons for change include strong design win momentum and innovation.
Adjusted Gross Profit $118 million or 45.6% adjusted gross margin, down 60 basis points year-over-year. Reasons for change include higher freight, tariff costs, and material costs due to geopolitical dynamics.
Adjusted EBITDA Margin 22%, up 70 basis points year-over-year. Reasons for change include strong profitability and operational efficiency.
Cash Flow Conversion Over 200% of net income. Reasons for change include strong profitability and deliberate investments in safety stocks.
Automation Enabling Technologies Revenue 7% year-over-year growth. Reasons for change include strong demand for advanced robotic applications and semiconductor applications.
Medical Solutions Revenue 15% year-over-year growth. Reasons for change include strong patient procedural growth rates and new product launches.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New product revenue: Increased by 50% year-over-year, with strong design win momentum and medical consumables growing double digits.
Next-generation insufflators: Set industry standards for patient safety, smoke evacuation, and surgical workflow optimization.
Intelligent laser beam steering subsystems: Launched for applications like AI GPU chips, aerospace manufacturing, and advanced semiconductor production.
Medical consumables: Now 15% of revenue, with sustained double-digit growth trajectory.
AI-driven Robotics & Automation: Strong growth in minimally invasive and robotic surgery markets, and accelerating double-digit growth in AI data center-related applications.
Precision Manufacturing: Returned to mid-single-digit growth, driven by automation and digitization of manufacturing lines.
Semiconductor markets: Experiencing an upswing with accelerating growth in AI data center-related applications.
Medical Solutions: Revenue grew 15% year-over-year, driven by new product launches and acquisitions.
Bookings growth: Increased by 37% year-over-year with a book-to-bill ratio of 1.10.
Cash flow performance: Operating cash flow increased by 63% year-over-year, with cash flow conversion to net income over 200%.
Manufacturing footprint transformation: Progressing with regional manufacturing initiatives, including two facility closures to improve gross margins.
Acquisitions: Focused on expanding in medical technologies, consumables, and embedded software, with a strong pipeline of opportunities.
High-growth market focus: Targeting AI-driven Robotics & Automation, minimally invasive surgery, digital manufacturing, and Precision Medicine, representing a $4 billion market opportunity by 2030.
Regional manufacturing initiative: Aimed at consolidating facilities to improve scale, talent, and gross margins.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Gross Margins: Gross margins were negatively impacted by higher freight, tariff costs, and material costs due to geopolitical dynamics. This resulted in a weaker-than-expected outcome and a lag in repricing orders to offset these costs.
Geopolitical and Trade Dynamics: The company faces challenges from trade dynamics, geopolitical tensions, and input cost volatility, which could impact operations and financial performance.
Manufacturing Footprint Transformation: The ongoing regional manufacturing initiative involves facility closures and consolidations, which could pose risks related to execution and potential disruptions during the transition.
Supply Chain Tightness: Investments in safety stocks for electronic components and rare earth materials indicate potential risks of supply chain disruptions.
Tariff and Cost Inflation: Rapidly shifting tariff rates and inflation have created challenges in managing costs and maintaining profitability.
Acquisition Strategy: The company’s focus on acquisitions to expand its business mix and technology leadership carries risks related to integration, execution, and achieving expected returns.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Organic Growth: Novanta expects organic growth to reach high single digits in the second quarter of 2026 and mid-single-digit organic growth or higher for the full year.
Revenue Projections: For the full year of 2026, Novanta expects GAAP revenue to be approximately $1,040 million to $1,055 million, representing reported growth greater than 7% and organic growth of up to 6%. For the second quarter of 2026, GAAP revenue is expected to be approximately $259 million to $264 million, representing year-over-year organic growth of 6% to 8% and reported revenue growth of up to 10%.
Adjusted EBITDA: For 2026, adjusted EBITDA is expected to be between $245 million and $250 million, representing year-over-year growth of 11% to 13%. For the second quarter of 2026, adjusted EBITDA is expected to be between $58 million and $62 million, representing high teens increase year-over-year.
Adjusted Earnings Per Share (EPS): For 2026, adjusted EPS is expected to be in the range of $3.50 to $3.65, representing year-over-year growth in the range of 6% to 11%. For the second quarter of 2026, diluted EPS is expected to be in the range of $0.81 to $0.86, representing year-over-year growth in the range of 6% to 13%.
Gross Margins: Gross margins for the second quarter of 2026 are expected to be approximately 45.5% to 46%, with meaningful stronger margin performance anticipated in the second half of the year.
Cash Flow Conversion: For 2026, Novanta expects cash flow conversion to achieve 100% or better as a percent of net income.
Market Trends and Business Segments: Strong demand is expected in AI-driven Robotics & Automation, minimally invasive and robotic surgery, digital manufacturing, and Precision Medicine. Robotics & Automation and Precision Manufacturing businesses are expected to benefit from the AI data center boom, with applications growing 20% year-over-year and further growth anticipated throughout 2026.
Acquisitions: Novanta plans to deploy meaningful capital in 2026 for acquisitions, focusing on medical technologies, medical consumables, and embedded software to enhance growth and revenue predictability.
Manufacturing Strategy: Novanta is progressing on its regional manufacturing initiative, with two facility closures expected in the second quarter of 2026, supporting a gross margin step-up in the second half of the year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: In the first quarter, we purchased approximately $18 million worth of company stock. While acquisitions remain our top capital allocation priority, we will continue to repurchase shares opportunistically when temporary dislocations create a compelling return on that capital. However, the strength of our current acquisition pipeline naturally tempers the pace of that buyback activity.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the significance of the 15% of total company revenue mentioned in the prepared remarks?
A:The 15% of total company revenue is driven by GenAI infrastructure investments and includes applications in Precision Manufacturing and Robotics & Automation. It encompasses advanced manufacturing techniques like deep UV, EUV lithography, GPU drilling, probe card production, and metrology for advanced 2-nanometer nodes. This segment grew 20% year-over-year in the first quarter and is expected to accelerate throughout the year.
Q:Can you elaborate on the NVIDIA AI lab announcement and its impact on the robotics space?
A:The company is the only servo drive manufacturer certified in the NVIDIA ecosystem, which adds credibility and avoids OEMs needing to verify claims. While applications are still in the prototype phase, the certification has generated interest. Meaningful prototype orders are expected, with more significant impact anticipated in 2027.
Q:What explains the difference between the 37% bookings growth and the organic revenue growth expectations?
A:The majority of orders will ship within the next 12 months. The bookings growth is partly due to a lower base in the first quarter of the previous year and some customers placing full-year orders in the first quarter. Typically, there is a two-to-three-quarter lag between bookings and revenue.
Q:Can you rank order the industrial opportunities contributing to revenue growth in 2026?
A:The opportunities are diverse and include EUV, DUV, warehouse automation, metal 3D printing components, GPU drilling, and humanoids. The company serves niche applications that collectively contribute to growth, driven by advanced manufacturing needs and GenAI infrastructure investments. No single opportunity stands out significantly.
Q:What is the opportunity in the Westwind business related to GPU drilling?
A:The Westwind business specializes in air bearing spindles for GPU board drilling, which requires precision and throughput for thick boards with 40 layers. The company is a leader in this niche, and the business has gained traction due to the growing GPU industry. However, it is part of a broader set of applications served by the company.
Q:What is the status of EUV and DUV business growth?
A:The core EUV and DUV business is growing in line with GenAI-driven growth rates. A new piece of business, delayed in the past, is expected to ramp up in the second half of the year and contribute meaningfully by 2027.
Q:What is the regional performance and impact of the regionalization strategy?
A:Sales to regions reflect shipments to customer factories and may not represent end-market demand. U.S. markets are strong, with growth in China driven by semiconductor and industrial applications, and growth in Europe primarily in the medical sector. Regionalization has helped align production with customer needs.
Q:What caused the price/cost timing impact, and how is it being addressed?
A:The impact was driven by sudden tariff changes and higher freight costs. The company has implemented new surcharge rates, increased product pricing, and adjusted backlog pricing. These measures are expected to mitigate the impact by the third quarter, with gross margins improving.
Q:Review of Unclear Management Responses
A:Management avoided directly ranking industrial opportunities contributing to revenue growth in 2026, stating that all opportunities are roughly similar in size and collectively contribute to growth. Additionally, they did not provide specific sizing for the Westwind business related to GPU drilling, emphasizing its niche leadership instead.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI center
AI manufacturing
Automation surgery
EUV lithography
GPU
GenAI
OEMs
Precision Manufacturing
Robotics Automation
beam steering
booking design
business confidence
card production
center application
consumables digit
digit booking
digit demand
direction
engine
exposure
fab
flow cash
generation insufflators
innovation
laser beam
macro environment
manufacturing Precision
momentum digit
node
packaging
probe card
record booking
release night
semiconductor wafer
set
step
trajectory
NOVT Transcript
Novanta Inc. (NOVT) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call and Q&A reveal a positive outlook for Novanta. Despite a slight decline in gross margin, strong growth is evident in multiple segments, such as Medical Solutions and Automation Enabling Technologies. The company's strategic initiatives, including regionalization and new product launches, are expected to drive future growth. The NVIDIA AI lab certification and strong bookings further bolster confidence. Although some uncertainties remain, particularly in cost management, the overall sentiment is optimistic, suggesting a likely stock price increase of 2% to 8% over the next two weeks.
Novanta Inc. (NOVT) Q4 2025 Earnings Call Transcript
Positive2-24
The earnings call indicates positive growth in key segments like Medical Solutions and Automation, with strong bookings and a positive book-to-bill ratio. Despite a decline in operating cash flow, the company shows strong demand and momentum across segments, especially in robotics and automation. The Q&A session reveals strategic positioning in high-growth areas and effective capital deployment plans. The positive sentiment is bolstered by optimistic guidance and strong market demand, suggesting a likely positive stock price movement over the next two weeks.
Novanta Inc. (NOVT) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call highlights strong new product revenue growth, improved customer bookings, and positive adjusted financial metrics despite temporary cash flow issues. The Q&A section reveals optimism about future growth in robotics and automation, with significant opportunities in the physical AI market. Margins are expected to improve with regional manufacturing strategies. While there are some concerns about specific segments, overall, the company's strategic initiatives and growth prospects suggest a positive stock price reaction.
Novanta Inc. (NOVT) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call presents a mixed picture. While there are positive aspects such as strong bookings growth, advanced surgery business growth, and promising new product launches, there are concerns with the decline in precision medicine sales and uncertain life sciences outlook. The Q&A reveals cautious guidance and unresolved tariff issues. The positive impact of the Kion acquisition and potential growth in warehouse robotics is offset by uncertainties in organic growth and market recovery, leading to a neutral stock price prediction.
NOVT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
